SS Innovations Secures $18.6M to Fuel Global Surgical Robotics Push

FORT LAUDERDALE, FL – March 09, 2026 – SS Innovations International, Inc. (Nasdaq: SSII) has secured a crucial $18.6 million in funding through a private placement, a strategic move designed to propel its affordable surgical robotics technology onto the world stage. The financing, marked by significant participation from the company's own leadership, provides a vital capital infusion as the firm prepares for anticipated entry into the lucrative and highly regulated United States and European Union markets.

The deal, which closed on March 6, saw the sale of over 5.7 million shares of common stock. It sends a powerful message to the market about the company's internal belief in its mission to democratize robotic surgery, a field long dominated by high-cost systems that are prohibitive for many healthcare institutions.

A Strong Vote of Insider Confidence

In a notable demonstration of conviction, the company’s top executives invested heavily in the private placement. Approximately $5.2 million of the total came directly from insiders, including Chairman and CEO Dr. Sudhir Srivastava, Vice-Chairman Dr. Frederic H. Moll, and director Tim Adams. These shares were purchased at an average price of $4.00 per share.

In contrast, the remaining $13.4 million, raised from a consortium of new and existing investors led by major shareholder Manipal Global Health Services, was secured at $3.00 per share. The premium paid by the company's leadership is a significant signal, often interpreted by analysts as a strong belief that the company's stock is undervalued and poised for future growth.

"Insider participation in this financing reflects our strong confidence in SS Innovations’ future and our commitment to democratizing access to world-class surgical robotic care," Dr. Srivastava stated in the official announcement. "We appreciate the continuing support of Manipal Global Health Services, a large existing shareholder, and welcome a respected group of new shareholders in the Company."

This level of insider buying provides a compelling counter-narrative to the company's recent stock performance, which has seen a 54% decline over the past year. While the company boasts impressive revenue growth—up 158% over the last twelve months to $36.1 million—it remains unprofitable. The fresh capital is therefore essential to fund operations and the costly process of international expansion as it works towards profitability.

The High-Stakes Path to Western Markets

The newly raised funds are earmarked for working capital and to advance the company's ambitious global growth initiatives. The primary focus is on navigating the rigorous regulatory pathways into the U.S. and E.U. SS Innovations is currently awaiting clearance from the U.S. Food and Drug Administration (FDA) and is pursuing a CE marking certification in the European Union for its flagship product, the SSi Mantra surgical robotic system.

The company submitted its 510(k) premarket notification to the FDA on December 5, 2025, seeking clearance for a wide range of procedures including general, urological, gynecological, and cardiac surgery. According to Dr. Srivastava, the company anticipates the FDA will complete its review by mid-2026. While the FDA has a target review time of 90 days for 510(k) submissions, the industry average for clearance is closer to six months, making the company's timeline ambitious but plausible.

Simultaneously, the firm is working towards the E.U.'s CE marking, which it also believes it can obtain in 2026. Securing these two approvals is the most critical near-term catalyst for SS Innovations. Gaining access to the North American and European markets, which together represent the largest share of the global surgical robotics industry, would unlock immense revenue potential and validate the SSi Mantra system on a global scale.

Challenging the Titans with an 'Affordable' Revolution

SS Innovations is entering a fiercely competitive market projected to be worth over $188 billion by 2032. The landscape is dominated by Intuitive Surgical, whose da Vinci systems held over 83% of the market share in 2024. However, the high cost of these systems, which can range from $1 million to $2.5 million per unit plus significant annual maintenance fees, creates a substantial barrier to entry for many hospitals worldwide.

This is where SS Innovations sees its opening. The company's core strategy revolves around affordability. The SSi Mantra system, already clinically validated in India across more than 100 different surgical procedures, is reportedly sold for less than one-third of the price of a da Vinci system in that market. By drastically lowering the upfront capital investment, SS Innovations aims to make advanced, minimally invasive robotic surgery accessible to a much broader segment of the global population, including in developing nations and smaller community hospitals in the West.

The SSi Mantra is a modular, multi-arm system featuring an open-faced surgeon command center, a large 3D 4K monitor, and compatibility with over 40 different types of surgical instruments. Its feature set is designed to compete directly with established players like Medtronic's Hugo RAS and CMR Surgical's Versius, both of which also aim to offer more flexible and cost-effective alternatives to the market leader.

The success of SS Innovations' strategy hinges on its ability to prove that lower cost does not mean a compromise in quality or patient outcomes. Its extensive clinical validation in India is a key part of this narrative, but achieving widespread adoption in the U.S. and E.U. will require convincing surgeons and hospital administrators who are accustomed to the long-established track record of competitors. The $18.6 million in new funding will be critical for building the sales, support, and training infrastructure necessary to compete effectively in these demanding markets.

The company has a clear vision and now, a reinforced balance sheet to pursue it. As the regulatory clocks in the U.S. and Europe tick down, the entire medical device industry will be watching to see if this Indian-headquartered innovator can successfully disrupt the status quo and truly begin the democratization of robotic surgery.